Crescent Capital BDC, Inc. (CCAP)
Crescent Capital: A Tactical 13% Yielding Case To Buy
Crescent Capital BDC, Inc. continues to underperform the index. Part of it is justified; part of it isn't. As of today, CCAP trades 40% below NAV and offers a yield of almost 13% that is underpinned by strong earnings coverage.
New Strong Sell Stocks for June 12th
CCAP, DAVA and RH have been added to the Zacks Rank #5 (Strong Sell) List on June 12, 2026.
Crescent Capital BDC (CCAP) Tops Q1 Earnings Estimates
Crescent Capital BDC (CCAP) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.45 per share a year ago.
Buy These 2 SBIC & Commercial Finance Stocks Despite Industry Weakness
Declining interest rates are likely to weigh on loan yields, while demand for personalized financing is expected to rise. The Zacks SBIC & Commercial Finance industry players like MAIN and CCAP are worth investing in.
Crescent Capital BDC, Inc. (NASDAQ:CCAP) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Crescent Capital BDC, Inc. (NASDAQ: CCAP - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six ratings firms that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, three have given a buy recommendation and one has given a strong buy
I'm Buying Up To 13% Yield For Future Retirement Income
Crescent Capital BDC and VICI Properties offer a barbell approach to income investing across interest rate cycles. CCAP provides a 13.1% yield, trades at a 33% discount to NAV, and maintains a conservative, first-lien, floating-rate loan portfolio. VICI delivers a 6.3% yield, robust AFFO growth, and long-term revenue stability via triple-net leases on premier gaming and experiential properties.
Crescent Capital BDC (CCAP) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Crescent Capital BDC (CCAP), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Crescent Capital BDC (CCAP) Moves to Buy: Rationale Behind the Upgrade
Crescent Capital BDC (CCAP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Down 12% in 4 Weeks, Here's Why Crescent Capital BDC (CCAP) Looks Ripe for a Turnaround
Crescent Capital BDC (CCAP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Crescent Capital BDC, Inc. (CCAP) Q4 2025 Earnings Call Transcript
Crescent Capital BDC, Inc. (CCAP) Q4 2025 Earnings Call Transcript
Cream Rises To The Top: 2 Top-Tier BDCs To Buy
Most BDC investors are value investors, who focus on income. The higher the multiple, the lower the yield - i.e., a mechanic that leads "bargain hunters" underemphasizing high P/NAV BDCs. In the article I detail why this kind of approach might be suboptimal.
Crescent Capital: Lower SOFR And 2026 Debt Wall Increase Dividend Coverage Risk
Crescent Capital's 27% NAV discount overstates upside; the BDC's yield looks attractive, but NII pressures and refinancing risks cap total returns. Portfolio risk and unitranche exposure are manageable, but mid-market sponsor lending is a crowded, commoditised space with no moat. Falling SOFR reduces net interest income, while 2026 debt maturities at higher rates further squeeze earnings and dividend coverage.
